Background {#s1}
==========

In spite of the excellent prognosis of pediatric B-ALL, disease relapse still reaches as high as 15--20% of these patients, which remains the major cause of leukemia-related death. High-risk B-ALL, such as Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL), is associated with higher rates of treatment failure, elevated minimal residual disease (MRD) levels, early relapse, and poor outcome ([@B1]). Activation of ABL/Src family kinases or JAK family kinases resulted from chromosome rearrangements occur frequently in patients with such characters, which can be therapeutically targeted by ABL/Src or JAK inhibitors, respectively ([@B2]). LYN is a member of the ABL/Src-tyrosine kinase family. Intragenic *LYN* rearrangement has been reported in 5 cases of hematopoietic malignancies so far ([@B3]--[@B8]) ([Table 1](#T1){ref-type="table"}). Although *in vitro* studies showed that the ABL/Src inhibitors were capable of blocking LYN\'s kinase activities, their clinical efficacy in real patients remains unknown ([@B9]). Here, we report a pediatric relapsed B-ALL with a t(8;17)(q12;p11.2)/*NCOR1-LYN* fusion showing robust and rapid response to dasatinib monotherapy.

###### 

Characteristics of the reported and the present cases with a LYN rearrangement.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Cases**                                        **Age(year)/gender**   **Disease**                            **Initial WBC counts**   **Karyotype**                                            **Fusion gene**   **Additional genetic changes**   **Relapse**   **TKI**     **Allo-HSCT**   **Clinical outcome**
  ------------------------------------------------ ---------------------- -------------------------------------- ------------------------ -------------------------------------------------------- ----------------- -------------------------------- ------------- ----------- --------------- --------------------------------------
  Tanaka et al. ([@B4])                            21/male                PMF[^\*^](#TN1){ref-type="table-fn"}   25.5 × 10^9^/L           46,XY,ins(12;8)(p13;q11q21)                              *ETV6-LYN*        Unknown                          No            Imatinib    Yes             Dead

  Telford et al. ([@B5])                           46/male                MPN[^\*^](#TN1){ref-type="table-fn"}   17.2 × 10^9^/L           46,XY,der(8)inv(q12.1q21.1)t\                            *ETV6-LYN*        Unknown                          No            No          No              Dead
                                                                                                                                          (8;12)(q12.1;p13),der(12)t(8;12)\                                                                                                                     
                                                                                                                                          (q12.1;p13)\[2\][^\#^](#TN2){ref-type="table-fn"}                                                                                                     

  Ma et al. ([@B6])                                41/male                AML                                    16.1 × 10^9^/L           47,XY,add(1)(p13), der(12)t(1;12)(p13;p12),+mar\         *ETV6-LYN*        No                               No            No          Yes             Unknown
                                                                                                                                          \[19\]/46,XY\[1\]                                                                                                                                     

  Reshmi et al. ([@B9])                            Unknown                B-ALL                                  Unknown                  Unknown                                                  *GATAD2A*-*LYN*   Unknown                          Unknown       Unknown     Unknown         Unknown

  Yano et al. ([@B7]) and Imamura et al. ([@B8])   8/female               B-ALL                                  293 × 10^9^/L            No metaphases                                            *NCOR1-LYN*       Deletion of *IKZF1, BTG1,CDK*\   Yes           No          Yes             CR[^\*^](#TN1){ref-type="table-fn"}
                                                                                                                                                                                                                     *N2A/2B*                                                                   

  The present case                                 6/male                 B-ALL                                  883 × 10^9^/L            46,XY,t(8;17)(q12;p11.2\[10\]/48,\                       *NCOR1-LYN*       Deletion of *IKZF1, CDKN2A*      Yes           Dasatinib   Yes             CMR[^\*^](#TN1){ref-type="table-fn"}
                                                                                                                                          idem,+der(17)t(9;17),+22/46,XY\[1\]) \[9\]/46, XY\[9\]                                                                                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*CR: complete remission; CMR: complete molecular remission; MPN: myeloproliferative neoplasm; PMF: primary myelofibrosis*.

*The intact karyotype was as: 46,XY,der(8)inv(q12.1q21.1)t(8;12)(q12.1;p13),der(12)t(8;12)(q12.1;p13)\[2\]/47,sl,+der(8)inv(8)t(8;12)\[5\]*.

*/48,sdl1,+der(8)inv(8)t(8;12)\[2\]/46,XY\[2\]*.

Case Presentation {#s2}
=================

The patient presented with swollen gums in March 2015 in an outside hospital. A complete peripheral blood cell count showed leukocytes 883 × 10^9^/L, Hb 56g/L and platelets 41 × 10^9^/L. Bone marrow histology showed 97.6% of blasts, which were negative for myeloid peroxidase. Flow cytometry demonstrated 91.3% of blasts that were positive for CD10, CD19, CD22, and cyCD79a. Karyotype analysis of the bone marrow specimen found only 2 metaphases with normal 46, XY karyotype. Fluorescence *in situ* hybridization (FISH) studies were negative for *BCR/ABL1, ETV6/RUNX1* translocations and *KMT2A* (*MLL), MYC* and *PDGFRB* rearrangements. Result of multiplex PCR covering 41 fusion genes commonly detected in ALL was negative. A diagnosis of B-ALL was established. The patient was treated with daunorubicin (DNR), vincrinstine (VCR), PEG asparaginase (PEG-ASP) according to the Chinese Children\'s Cancer Group (CCCG)-2015-ALL protocol ([@B10]) and achieved complete hematological remission at the end of induction chemotherapy. Minimal residual disease (MRD) based on flow cytometry remained positive (≥1 × 10^−4^) during the subsequent chemotherapy. HSCT was not performed due to parents\' concern on potential HSCT-related complications. The patient received 3 years\' chemotherapy following the CCCG-2015-ALL protocol. Consolidation chemotherapy included 4 cycles of high-dose methotrexate (MTX), followed with 5 cycles of combined chemotherapy with dexamethasone (Dex), DNR, VCR, PEG-ASP, and cytarabine. Maintenance therapy comprised cycles of 6-mercaptopurine and MTX, which was completed in March 2018. Unfortunately, disease relapsed in September 2018 (42 months after the initial diagnosis), and he was admitted to our hospital. A complete peripheral blood cell count showed leukocytes 44.8 × 10^9^/L, Hb 64 g/L and platelets 99 × 10^9^/L. Blast counts of bone marrow were 71.5% by histology and 84.1% by flow cytometry, blasts were positive for CD10, CD19, CD22, CD38, and cyCD79a and negative for CD20. Chromosome analysis of the bone marrow specimen showed 46,XY,t(8;17)(q12;p11.2),9qh+\[10\]/48,idem,+der(17)t(8;17),+22\[9\]/46,XY,9qh+\[1\] ([Figure 1A](#F1){ref-type="fig"}). Fluorescence *in situ* hybridization (FISH) analysis with a panel of FISH probes specific to Ph-like B-ALL, including *ABL1, ABL2, JAK2, CRLF2*, and *EPOR*, were all negative (data not shown). FISH with a chromosome 17 centromere probe and a *TP53* probe showed that one of the *TP53* signals was relocated to the der ([@B8]) chromosome, consistent with a chromosome 17 breakpoint which was centromeric to *TP53* ([Figure 1B](#F1){ref-type="fig"}). Because *NCOR1* is located at 17p11.2, we assumed that the t(8;17)(q12;p11.2) led to *NCOR1/LYN* fusion. PCR with primers specific to *NCOR1* (5′ -CGTACAACTCTGCTTCCATGTCTC-3′) and *LYN* (5′-GCCACCTTGGTACTGTTGTTATAGTAAC-3′) showed a sharp band, with a size consistent with the *NCOR1/LYN* fusion; while no such band was detected using placenta control RNA template ([Figure 1C](#F1){ref-type="fig"}). Sanger sequencing of the PCR band confirmed that the *NCOR1* exon 34 was fused to *LYN* exon 8 ([Figure 1D](#F1){ref-type="fig"}). In addition to the *NCOR-LYN* fusion, several gene mutations were also observed in a concurrent next-generation sequencing assay, *ARID1A* Ala41Val with a variant allele frequency (VAF) of 63.1%, *KRAS* Gly12Ala with VAF of 0.6%, *NRAS* Gln61His with VAF of 2.2%, *PAX5* Arg140Leu with VAF of 39.9% and *ZNF292* Asn1695del with VAF of 43.4% (data not shown), and deletion of *CDKN2A* and *IKZF1* ([Figure 2A](#F2){ref-type="fig"}). Unfortunately, we are unable to determine whether these genomic changes, including the *NCOR-LYN* fusion, are also present in the diagnostic specimen, due to lack of sample.

![G-banding analysis of the BM sample at relapse, which showed the balanced translocation t(8;17)(q12;p11.2). **(B)** FISH with a chromosome 17 centromere probe (green) and a *TP53* probe (red) showed one of the *TP53* signals on the der ([@B8]) chromosome, suggesting that the chromosome 17p breakpoint is centromeric to *TP53* on 17p13. **(C)** RT-PCR showed various levels of *NCOR1-LYN* fusion transcript in bone marrow specimens. Lane 1: relapse sample; lane 2: 2 weeks after dasatinib; lane 3: 1 month post allo-HSCT; lane 4: 2 months post allo-HSCT; lane 5: 3 months post allo-HSCT; lane 6: 10 months post allo-HSCT; lane 7: negative control. **(D)** Sanger sequencing result of the *NCOR1-LYN* fusion gene, confirming a fusion between exon 34 of *NCOR1* and exon 8 of *LYN*. **(E)** Schematic representation of the predicted domain structure of the NCOR1-LYN fusion.](fonc-10-00359-g0001){#F1}

![NGS analysis of the bone marrow sample at relapse showed deletions of CDKN2A and IKZF1. **(B,C)** Bone marrow smears before and after dasatinib therapy.](fonc-10-00359-g0002){#F2}

The patient was initially treated with mitoxantrone, vincristine and Dex. After completion of chemotherapy, bone marrow morphology still showed 61.5% of blasts ([Figure 2B](#F2){ref-type="fig"}). The patient was then treated with dasatinib (60 mg/m^2^, once daily) as monotherapy. Two weeks after dasatinib treatment, bone marrow aspirates showed only 1% of blasts by histology ([Figure 2C](#F2){ref-type="fig"}) and 0.1% of blasts by flow cytometry. Karyotype analysis of the bone marrow was normal. RT-PCR assays showed significantly decreased fusion transcript ([Figure 1C](#F1){ref-type="fig"}). Haploidentical HSCT was performed 80 days after dasatinib therapy. No symptoms of graft vs. host disease were observed. Therefore, dasatinib was started 8 weeks post allo-HSCT for prevention of relapse. He has been tolerated with dasatinib very well and remained in MRD negative remission for 10 months now post allo-HSCT, based on both flow cytometry and RT-PCR assays ([Figure 1C](#F1){ref-type="fig"}). Timeline of the treatment was shown in [Supplementary Figure 1](#SM1){ref-type="supplementary-material"}.

Discussion {#s3}
==========

*LYN*, located on 8q12.1, is highly expressed in hematopoietic cells and plays roles in B-cell signaling, mast cell degranulation and erythroid differentiation ([@B11]). Four major functional domains of LYN include Src Homology 2 (SH2), SH3, proline-rich hinge region (P), and tyrosine kinase domain. In its inactivation status, SH2 and SH3 bind to LYN\'s phosphorylated carboxyl terminus (Y508) and P region, respectively, to ensure an inactivation conformation. LYN is activated when Y508 is dephosphorylated or the intramolecular binding released by competitive interaction with SH2 and/or SH3 ([@B12]). NCOR1 plays important roles in cellular metabolism, cell proliferation and neural stem cell differentiation ([@B13]--[@B15]). NCOR1 interacts with nuclear hormone receptors and recruits multiple histone deacetylase enzymes including HDAC1-4 and HDAC7 to form inhibitory chromatin structures. Four major functional domains of NCOR1 include repression domains (RD), coiled-coil domains (CC), SANT-like domains (SA) (for HDAC binding) and interactive domains (ID) (for nuclear hormone receptor binding). NCOR1-LYN fusion contains the 5′*NCOR1*, including RD, SA, and CC domains, and the 3′ *LYN* with an intact protein kinase domain ([Figure 1E](#F1){ref-type="fig"}). Because CC function as oligomerization domains for a wide variety of proteins and are capable of both homo-oligomerization and hetero-oligomerization ([@B13]), we propose an oncogenic model that NCOR1-LYN homo-dimerization, driven by the CC domains from NCOR1, leads to trans-autophosphorylation within the activation loop of LYN kinase domain and constitutive LYN signaling.

Although *LYN* is over-expressed in acute myeloid leukemia (AML) and Ph^+^-ALL, intragenic rearrangements involving *LYN* are rare, with only 5 cases reported so far ([Table 1](#T1){ref-type="table"}) ([@B4]--[@B8]). The fusion partners of *LYN* include *GATAD2A, ETV6*, and *NCOR. GATAD2A-LYN* was reported in a patient with B-ALL with no clinic details of the disease ([@B9]). *ETV6-LYN* was reported in 2 patients with MPN and 1 patient with *de novo* AML. All three cases were resistant to conventional chemotherapy, progressed rapidly and succumbed to diseases in a short period of time ([@B4]--[@B6]). One of these patients was treated with imatinib with no response ([@B4]), although dasatinib was not used in any of these cases. Interestingly, *ETV6-LYN* transfected murine Ba/F3 hematopoietic cells were sensitive to dasatinib but not imatinib ([@B4]). Yano et al. reported the first B-ALL case with a *NCOR1-LYN* fusion gene ([@B7], [@B8]). Thus, our patient here confirmed that the *NCOR1-LYN* fusion is a recurrent event in B-ALL. Both patients had the same breakpoints at intron 7 of *LYN* and intron 34 of *NCOR1*. *IKZF1* gene defects occur in about 70% of Ph positive and Ph-like ALL cases and mediate therapy resistance ([@B16]). Therefore, we consider that *IKZF1* deletion might contribute to chemoresistance of this patient. Also, deletions of *IKZF1* and *CDKN2A* were observed in both cases. Clinically, both were pediatric B-ALL with high WBC counts at diagnosis who relapsed after chemotherapy. The previous case didn\'t receive tyrosine kinase inhibitors and survived after allo-HSCT ([Table 1](#T1){ref-type="table"}). Together these studies suggest that the pediatric B-ALL with *NCOR-LYN* fusion may have similar oncogenic mechanisms and clinical course.

Conclusion {#s4}
==========

In summary, we present the first case of B-ALL with *NCOR1-LYN* fusion who showed a quick and robust response to dasatinib. Whether or not leukemia with *LYN* overexpression, in the absence of *LYN* rearrangement, is responsive to dasatinib is probably worth further evaluation.
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Timeline of the treatment.

###### 

Click here for additional data file.
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